Related Experiment Video
Updated: Oct 17, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Targeting ARID1A mutations in cancer
Jaren Mullen1, Shumei Kato1, Jason K Sicklick2
1Center for Personalized Cancer Therapy, UCSD Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Abstract:
Genes encoding SWI/SNF chromatin remodeling complex subunits are collectively mutated in approximately 20% of human cancers. ARID1A is a SWI/SNF subunit gene whose protein product binds DNA. ARID1A gene alterations result in loss of function. It is the most commonly mutated member of the SWI/SNF complex, being aberrant in ∼6% of cancers overall, including ovarian clear cell cancers (∼45% of patients) and uterine endometrioid cancers (∼37%). ARID1A has a crucial role in regulating gene expression that drives oncogenesis or tumor suppression. In particular, ARID1A participates in control of the PI3K/AKT/mTOR pathway, immune responsiveness to cancer, EZH2 methyltransferase activity, steroid receptor modulation, DNA damage checkpoints, and regulation of p53 targets and KRAS signaling. A variety of compounds may be of benefit in ARID1A-altered cancers: immune checkpoint blockade, and inhibitors of mTOR, EZH2, histone deacetylases, ATR and/or PARP. ARID1A alterations may also mediate resistance to platinum chemotherapy and estrogen receptor degraders/modulators.
Insights
Mutations in the ARID1A gene, a key component of the SWI/SNF complex, are common in cancers like ovarian clear cell and uterine endometrioid types. These alterations impact gene expression and suggest potential therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The SWI/SNF chromatin remodeling complex is frequently altered in human cancers, with ARID1A being the most commonly mutated subunit.
- ARID1A gene alterations lead to loss of function and are observed in approximately 6% of all cancers, notably ovarian clear cell (45%) and uterine endometrioid (37%) cancers.
Purpose of the Study:
- To review the critical role of ARID1A in gene expression regulation relevant to oncogenesis and tumor suppression.
- To identify potential therapeutic strategies and drug targets for ARID1A-altered cancers.
Main Methods:
- Literature review and analysis of existing data on ARID1A mutations and their functional consequences.
- Examination of ARID1A's involvement in key cellular pathways and its implications for cancer treatment.
Main Results:
- ARID1A mutations affect critical pathways including PI3K/AKT/mTOR, immune response, EZH2 activity, and DNA damage response.
- ARID1A alterations are associated with resistance to platinum chemotherapy and endocrine therapies.
Conclusions:
- Targeting pathways regulated by ARID1A, such as mTOR and EZH2, and utilizing immune checkpoint blockade may benefit patients with ARID1A-altered cancers.
- Understanding ARID1A's role is crucial for developing novel therapeutic approaches and overcoming treatment resistance.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...